Arkadiusz Dudek is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 329 publications with 9,776 citations (h-index 47); ClinicalTrials.gov lists 14 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 19 Oct 2022.
Clinical trials
- Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Sponsor: Arkadiusz Z. Dudek, MD
- Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Sponsor: Arkadiusz Z. Dudek, MD
- Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
Sponsor: TTC Oncology, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.1%PD-1 inhibitor31.8%Pembrolizumab100%Part B, office-administered≥33 patientsCD38-directed Cytolytic Antibody19.1%Daratumumab100%Part B, office-administered≥30 patients+ 5 more classes in this area
Metabolism & gastrointestinal
23.6%Other antiemetics19.5%Fosaprepitant100%Part B, office-administered≥32 patientsSerotonin-3 Receptor Antagonist4%Palonosetron hcl64%Ondansetron hydrochloride34%Ondansetron Hcl2%Part D + Part B≥64 patients+ 1 more class in this area
Sensory organs
2.7%Corticosteroid2.7%Dexamethasone sodium phosphate100%Part B, office-administered≥67 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2004–2006 per NIH RePORTER. The latest:
- AUTOLOGOUS LMI VACCINE FOR MELANOMA AND RENAL CELL CARCINOMA
University of Minnesota
FY2006$2,510M01RR000400 - AUTOLOGOUS LMI VACCINE FOR MELANOMA AND RENAL CELL CARCINOMA
University of Minnesota Twin Cities
FY2005$32,904M01RR000400 - Autologous LMI Vaccine for Melanoma and Renal Cell Carcinoma
University of Minnesota Twin Cities
FY2004$57,666M01RR000400
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”